carvedilol / Generic mfg. - LARVOL DELTA

Chronic Carvedilol in Pediatric Dilated Cardiomyopathy: How Should We Interpret Long-Term Tolerability? (PubMed, Pediatr Cardiol) - No abstract available

Journal • Review • Cardiomyopathy • Cardiovascular • Pediatrics

Are beta-blockers safe early after heart transplantation? (TTS 2026) - "This includes excess bradycardia and hypotension, especially if previous amiodarone was given prior to HTx. This study confirms that BB therapy used early after heart transplant must be used with caution, as exaggerated responses are experienced."

Cardiovascular • Congestive Heart Failure • Heart Failure • Hypotension • Transplantation

A CASE OF BRADYCARDIA, RENAL FAILURE, ATRIOVENTRICULAR NODAL BLOCKADE, SHOCK, AND HYPERKALEMIA (BRASH) SYNDROME SECONDARY TO CARVEDILOL (CHEST 2026) - No abstract available

Clinical • Cardiovascular • Renal Disease

BRAVE-HCM: The Therapeutic Value of Mavacamten in Hypertrophic Cardiomyopathy With Mid-to-Apical Left Ventricular Obstruction (clinicaltrials.gov) - P4 | N=132 | Enrolling by invitation | Sponsor: Second Affiliated Hospital, Zhejiang University, School of Medicine | Not yet recruiting ➔ Enrolling by invitation | Trial primary completion date: Jul 2026 ➔ Nov 2026

Enrollment open • Real-world evidence • Trial primary completion date • Cardiomyopathy • Cardiovascular • Hypertrophic Cardiomyopathy

Effect of empagliflozin with or without carvedilol on tricuspid regurgitation and right ventricular remodeling: PROVE trial. (PubMed, J Cardiovasc Imaging) - P3 | "Carvedilol SR, empagliflozin, or their combination showed no significant reduction in RV volumes, but empagliflozin significantly reduced TR severity in patients with functional TR."

Journal • Atrial Fibrillation • Cardiovascular • Diabetes • Metabolic Disorders

Possible Interaction of the Gut-selective Antibiotic Rifaximin with Carvedilol Associated with Transient Indirect Hyperbilirubinemia: A Case Report. (PubMed, Curr Drug Saf) - "This appears to be the first report of new-onset indirect hyperbilirubinemia with rifaximin in the presence of carvedilol in a patient with chronic liver disease of autoimmune etiology. Carvedilol-mediated P-glycoprotein inhibition represents a biologically plausible but unproven mechanism for overexposure to rifaximin. Clinical studies are warranted to assess the potential consequences of P-glycoprotein-mediated modulation of rifaximin pharmacokinetics in patients with chronic liver and renal disease."

Journal • Chronic Kidney Disease • CNS Disorders • Hematological Disorders • Hepatic Encephalopathy • Hepatology • Immunology • Nephrology • Renal Disease

Unusual Spinal Epidural and Paraspinal Venous Engorgement Secondary to Hepatosplenic Schistosomiasis: A Rare Cause of Severe Low Back Pain. (PubMed, Clin Case Rep) - "MRI revealed dilated epidural veins and neural foraminal narrowing. The patient was managed conservatively with analgesia and carvedilol for portal hypertension and subsequently experienced complete resolution of back pain."

Journal • Back Pain • Cardiovascular • Hypertension • Infectious Disease • Lumbar Back Pain • Musculoskeletal Pain • Pain • Portal Hypertension

Dissolution Enhancement by Binding Agents: A Potential Shortcut to Improving Bioavailability? (PubMed, AAPS J) - "Loperamide hydrochloride, fenofibrate, compound c0 (a drug candidate) and carvedilol were chosen for this study as poorly water-soluble model compounds. Although solubilities and dissolution profiles of the model compounds were mostly improved by the binders, correlation between solubility in buffers and dissolution from the tablets in biorelevant FaSSIF-V1 was poor, indicating that dissolution experiments may be a better screening tool than solubility experiments. An important conclusion of these studies is that it is possible to increase the rate, and in some cases, the extent of dissolution of four poorly soluble drugs using wet granulation with polymeric binders, followed by tablet compression - a simple and cost-effective approach to improving drug performance."

Journal

Long-term clinical outcomes of carvedilol versus nebivolol in patients with ST-segment elevation myocardial infarction treated with second-generation drug-eluting stents: insights from a Korean nationwide multicenter prospective registry. (PubMed, Front Cardiovasc Med) - "All-cause mortality (4.4% vs. 3.4%; HR: 1.315, 95% CI: 1.102-1.569, p = 0.002) and revascularization (7.0% vs. 6.2%, p = 0.043; HR: 1.15, 95% CI: 1.00-1.32, p = 0.043) were also higher in the nebivolol group compared with carvedilol. In this contemporary cohort of patients with STEMI treated with DES, carvedilol was associated with better long-term clinical outcomes, including lower risks of MACE and all-cause mortality, compared with nebivolol."

Clinical data • Journal • Cardiovascular • Congestive Heart Failure • Heart Failure • Hematological Disorders • Myocardial Infarction • Thrombosis

Construction of α1A-Adrenoceptor-Based Stationary Phase Triggered by the Ultrahigh Affinity Protein Pair Colicin E7 Dnase /IM7 for Targeted Bioactive Compound Screening in Herba leonuri. (PubMed, J Sep Sci) - "Under the desired condition, carvedilol gave the association constant of (11.56±0.7) × 105 M-1 indicating immobilization of α1A-AR via this method still enhances its binding activity to drugs. Furthermore, stachydrine and leonurine were obtained as the bioactive compounds targeting the immobilized α1A-AR. Our study is expected to offer a versatile platform to achieve effective and specific immobilization of other functional proteins, thus enabling easy separation of the target compound from complex systems."

Journal

Non-ischemic Dilated Cardiomyopathy In A 42-year-old The Malignant Phenotype And The Role Of Des Gene Analysis (HFSA 2026) - "Despite optimization on quadruple goal-directed medical therapy (GDMT)—including sacubitril/valsartan, carvedilol, spironolactone, and dapagliflozin, the patient's structural and electrical instability persisted.Investigations and Coronary angiography confirmed normal coronary arteries, and a comprehensive toxicology workup was negative. This case highlights the necessity of early geneticist involvement and testing in young patients with unexplained HFrEF, particularly when a malignant phenotype (concomitant stroke and arrhythmia) is present. Beyond confirming a structural etiology, genetic identification shifts management toward early heart transplant evaluation and mandates life-saving cascade screening for family members. Early identification allows for pre-symptomatic monitoring and intervention in relatives at risk for sudden cardiac death, effectively transforming a diagnostic mystery into a proactive, family-centered prevention strategy."

Cardiomyopathy • Cardiovascular • CNS Disorders • Congestive Heart Failure • Heart Failure • Ventricular Tachycardia

Effect of carvedilol versus placebo on cardiac function in anthracycline-exposed survivors of childhood cancer (PREVENT-HF): a randomised, controlled, phase 2b trial. (PubMed, Lancet Oncol) - P2b | "Low-dose carvedilol appears to be safe in long-term childhood cancer survivors at risk for heart failure, but did not result in significant improvement of LVWT/Dz compared with placebo. These results do not support the use of carvedilol for secondary heart failure prevention in anthracycline-exposed childhood cancer survivors."

Journal • P2b data • Cardiovascular • Congestive Heart Failure • Heart Failure • Hematological Malignancies • Leukemia • Lymphoma • Musculoskeletal Pain • Oncology

Comparative Cardiovascular Outcomes of Verapamil and Carvedilol in MINOCA-Related Coronary Microvascular Dysfunction - A Propensity-Matched Cohort Study (AHA 2026) - "Abstract is embargoed at this time."

Cardiovascular

Metabolic Disturbances Associated with Beta-Blocker Therapy: New Insights from a Large-Scale Pharmacovigilance Study. (PubMed, Pharmaceuticals (Basel)) - "Objective: We investigated the association between selected BBs and metabolic diseases using a large pharmacovigilance database and compared the reporting profiles of metoprolol (MET), carvedilol (CAR), bisoprolol (BIS), and nebivolol (NEB). MET and to a lesser extent CAR were associated with higher reporting odds of metabolic diseases, whereas BIS and especially NEB demonstrated more favorable reporting profiles. Although causality cannot be established from spontaneous reporting data, these findings support individualized BB selection and closer metabolic monitoring in patients with cardiometabolic risk factors."

Adverse events • Journal • Cardiovascular • Diabetes • Dyslipidemia • Genetic Disorders • Hypertriglyceridemia • Inflammation • Metabolic Disorders • Obesity • Type 2 Diabetes Mellitus

Exploring the structure, thermophysical properties, and solvent capacity of the pure cinnamyl alcohol, and its hydrophobic eutectic mixtures with thymol. (PubMed, Food Res Int) - "Except for carvedilol, the solubility (in mole fraction) increased with the cinnamyl alcohol ratio. Overall, the results identify pure cinnamyl alcohol and cinnamyl alcohol:thymol mixtures as promising eco-friendly solvents with significant potential for improving the solubility of poorly soluble pharmaceuticals."

Journal

Comparative clinical outcomes of carvedilol versus bisoprolol in STEMI survivors after primary PCI: a propensity-score matched analysis (ESC 2026) - "In STEMI survivors treated with contemporary primary PCI, carvedilol and bisoprolol demonstrated comparable 3-year clinical outcomes. This prognostic parity allows clinicians to individualize beta-blocker selection without compromising long-term survival or ischemic protection."

Clinical • Clinical data • Cardiovascular • Myocardial Infarction

Beta‑blocker tapering and symptom improvement in dysautonomic dysfunction patients (ESC 2026) - "Cardioselective beta‑blockers were commonly used (metoprolol succinate 33 %, metoprolol tartrate 29 %, bisoprolol 28 %, carvedilol 11 %). Symptom improvements were observed across the full spectrum of dose reduction; this highlights the synergistic value of combining beta‑blocker tapering with multimodal rehabilitation. Prospective controlled studies are warranted to confirm these observations and to optimise pharmacological strategies in dysautonomic dysfunction management."

Clinical • Cardiovascular

Clinical outcomes of carvedilol versus metoprolol in patients with heart failure with preserved ejection fraction following myocardial infarction (ESC 2026) - "These findings suggest that in HFpEF patients post-MI, beta-blocker selection may not meaningfully impact survival or ischemic risk, but metoprolol may confer a lower risk of heart failure exacerbations. Prospective trials are warranted to clarify whether beta-1 selective versus nonselective beta-blockade differentially influences long-term outcomes in this population."

Clinical • Clinical data • Atrial Fibrillation • Cardiovascular • Congestive Heart Failure • Heart Failure • Myocardial Infarction • Ventricular Tachycardia

Low-intensity pulsed ultrasound-mediated nose-to-brain co-delivery of β-blockers and aPD-L1 enhances glioblastoma immunotherapy. (PubMed, Nat Commun) - "A bionic nanovesicle (iRGD-anti-programmed cell death ligand 1 (aPD-L1) & carvedilol (β-blocker) @ macrophage-derived extracellular vesicles, iMPC) is designed to co-deliver carvedilol for β-receptor blockade to reduce T-cell exhaustion, and aPD-L1 to enhance T-cell anti-tumor activity in orthotopic glioblastoma (GBM) mice during the two-hour window for NMB opening...Reactivating T cells significantly enhances immunotherapy, leading to a 40% tumor reduction, extended survival, and long-term immune memory in orthotopic GBM mice. Overall, the LIPUS-mediated NMB opening strategy notably enhances nose-to-brain drug delivery efficiency, offering a promising platform for treating brain diseases."

Journal • Brain Cancer • CNS Disorders • Glioblastoma • Oncology • Solid Tumor

Flood Syndrome Secondary to BuddâChiari Syndrome: A Case Report (ACG 2026) - "Prophylactic ceftriaxone, metronidazole were given and patient was optimized on a spironolactone and torsemide regimen to reduce ascitic fluid pressure. The patient was instructed on regular follow-up and strict compliance to her BCS regimen including rivaroxaban, carvedilol...This case expands the etiological spectrum of Flood syndrome and emphasizes that BCS should be considered as a potential cause in patients presenting with spontaneous umbilical ascitic leakage. Figure: Picture depicting the sinus tract on skin"

Case report • Clinical • Cardiovascular • Fibrosis • Gastroenterology • Hepatology • Immunology • Infectious Disease • Portal Hypertension • Thrombosis

Large Hiatal Hernia Causing Non-Cirrhotic Portal Hypertension via Mechanical Obstruction: A Case Study (ACG 2026) - "Although the patient did not have cirrhosis, carvedilol 6.25 mg twice daily was initiated for varices/portal hypertension management...D) Coronal image of a contrast enhanced CT shows severe focal narrowing of the main portal vein against the median arcuate ligament (black arrows). The main portal vein diameter is 2.2 cm."

Case study • Clinical • Cardiovascular • Colorectal Cancer • Fibrosis • Gastric Cancer • Gastroenterology • Gastroesophageal Reflux Disease • Gastrointestinal Disorder • Hepatology • Immunology • Portal Hypertension • Prostate Cancer • Rectal Cancer • Solid Tumor • Thrombosis

Carvedilol vs Endoscopic Variceal Band Ligation for Primary and Overall Prophylaxis of Esophageal Variceal Bleeding in Patients With Cirrhosis: Updated Systematic Review and Meta-Analysis of Randomized Controlled Trials (ACG 2026) - "Ten articles (n=1501; 750 in carvedilol and 751 in VBL) met inclusion criteria. Follow-up ranged between 12 months to 31 months and the mean (SD) age for Carvedilol and VBL cohorts was 52.62 (3.46) years and 51.98 (3.69) years, respectively. Variceal bleeding (OR: 1.07, 95% CI: 0.78 - 1.48; p=0.67; I 2 =24% ), bleeding mortality (OR: 1.23, CI: 0.68 - 2.22; p=0.49; I 2 =1% ), overall mortality (OR: 1.22, CI: 0.69 - 2.16; p=0.50; I 2 =62% ), TIPS requirement (OR: 0.57, CI: 0.26 - 1.23; p=0.15; I 2 =0% ) and treatment related adverse events (OR: 0.92, CI: 0.43 - 1.98; p=0.83; I 2 =86% ) were not significantly different between the two groups."

Retrospective data • Review • Cardiovascular • Fibrosis • Gastroenterology • Hematological Disorders • Hepatology • Immunology • Portal Hypertension

Potential Association of Non-Selective Beta-Blockers With Hepatic Encephalopathy in Cirrhosis: A Systematic Review and Meta-Analysis (ACG 2026) - "Search terms included: (cirrhosis OR liver cirrhosis OR hepatic cirrhosis) AND (ânonselective beta blockerâ OR NSBB OR propranolol OR nadolol OR carvedilol). Our search identified 598 articles, of which 12 studies (2 RCTs and 10 cohort studies) comprising a total 4,358 patients met inclusion criteria. Both RCTs had low risk of bias. Among cohort studies, 6 were graded good quality and 4 fair quality."

Retrospective data • Review • Cardiovascular • CNS Disorders • Fibrosis • Gastroenterology • Hematological Disorders • Hepatic Encephalopathy • Hepatology • Immunology • Liver Cirrhosis • Portal Hypertension

Harmless or Harmful? A Case Report on Pseudomelanosis Duodeni (ACG 2026) - "She reported adherence with her medications including carvedilol, hydralazine, torsemide, semaglutide, and ferrous sulfate...PD appears to occur predominantly in middle-age females and have a strong association with hypertension and diabetes mellitus and the use of certain medications such as hydralazine, ferrous sulfate, and sulfur-containing loop diuretics such as furosemide or torsemide...Therefore, the purpose of this case report is to bring awareness about PD and highlight the importance of distinguishing it from duodenal melanoma to avoid unnecessary work-up as it is benign and requires no further work-up or treatment. Figure: Abnormal mucosa in the duodenum"

Case report • Clinical • Cardiovascular • Congestive Heart Failure • Constipation • Diabetes • Dyspepsia • Gastroenterology • Gastrointestinal Disorder • Heart Failure • Hypertension • Melanoma • Metabolic Disorders • Solid Tumor

Sodium-Glucose Cotransporter-2 Inhibitors and Outcomes Across Recorded Carvedilol Strengths in Cirrhosis: A Propensity-Matched Global Cohort Study (ACG 2026) - "After matching, 17,464 patients were included in each main cohort. SGLT2i exposure was associated with lower mortality (22.2% vs 29.8%; OR 0.671, 95% CI 0.639-0.704), paracentesis (7.2% vs 9.6%; OR 0.730, 95% CI 0.673-0.792), spontaneous bacterial peritonitis (2.2% vs 3.2%; OR 0.677, 95% CI 0.592-0.775), and hepatorenal syndrome (2.6% vs 3.0%; OR 0.859, 95% CI 0.755-0.978). One-year and 3-year analyses showed lower mortality hazards with SGLT2i exposure (HR 0.577 and 0.600; both p< 0.001)."

Clinical • Cardiovascular • CNS Disorders • Fibrosis • Heart Failure • Hepatic Encephalopathy • Hepatocellular Cancer • Hepatology • Hypotension • Immunology • Nephrology • Portal Hypertension • Renal Disease • Solid Tumor